Drug discovery, gene editing, and healthcare innovation from bench to bedside.
Generated September 11, 2026
| # | Ticker | Name | Industry | Stage | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | Total | Price | 1yr Chg | 30d Target | 90d Ret | Signal | Mkt Cap | TTM EPS | Fwd EPS | EPS Growth | Next Earnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Incorporated | Biotechnology | AdvancingMomentum Trend | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 90 | $515.44 | +30.1% | ▲ $581.99 | +31.5% | BUY | $130.6B | $17.15 | $21.77 | +8.0% | 2026-11-02 |
| 2 | LLY | Eli Lilly and Company | Drug Manufacturers - General | AdvancingMomentum Trend | 5 | 10 | 10 | 10 | 5 | 10 | 10 | 10 | 5 | 75 | $1,115.70 | +54.4% | ▲ $1429.96 | +55.5% | BUY | $994.9B | $29.77 | $47.26 | +26.2% | 2026-10-29 |
| 3 | AMGN | Amgen Inc. | Drug Manufacturers - General | AdvancingMomentum Trend | 0 | 10 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 75 | $377.35 | +36.7% | ▲ $465.64 | +19.5% | BUY | $204.0B | $16.09 | $24.41 | +64.9% | 2026-11-03 |
| 4 | ABBV | AbbVie Inc. | Drug Manufacturers - General | AdvancingMomentum Trend | 0 | 10 | 5 | 10 | 10 | 10 | 10 | 10 | 5 | 70 | $257.12 | +24.7% | ▲ $288.01 | +14.4% | BUY | $454.4B | $3.54 | $16.28 | +290.4% | 2026-10-29 |
| 5 | REGN | Regeneron Pharmaceuticals, Inc. | Biotechnology | AdvancingMomentum Trend | 10 | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 | 70 | $781.49 | +37.0% | ▲ $846.60 | +20.3% | HOLD | $80.5B | $40.39 | $60.61 | -4.5% | 2026-10-28 |
| 6 | ISRG | Intuitive Surgical, Inc. | Medical Instruments & Supplies | DecliningContrarian Setup | 10 | 10 | 5 | 10 | 5 | 5 | 10 | 5 | 5 | 65 | $369.15 | -20.9% | ▼ $308.52 | +7.1% | WEAK | $132.3B | $8.73 | $12.07 | +26.5% | 2026-10-20 |
| 7 | NVO | Novo Nordisk A/S | Drug Manufacturers - General | ToppingDistribution Risk | 0 | 5 | 5 | 10 | 5 | 10 | 10 | 10 | 5 | 60 | $43.07 | -18.1% | ▲ $47.65 | -0.1% | HOLD | $190.3B | $4.07 | $3.42 | -20.6% | 2026-11-04 |
| 8 | JNJ | Johnson & Johnson | Drug Manufacturers - General | AdvancingMomentum Trend | 5 | 5 | 5 | 5 | 5 | 10 | 10 | 5 | 5 | 55 | $265.58 | +52.2% | ▲ $279.48 | +8.9% | HOLD | $640.0B | $8.61 | $12.31 | -0.9% | 2026-10-13 |
| 9 | MDT | Medtronic plc | Medical Devices | ToppingDistribution Risk | 5 | 5 | 10 | 10 | 5 | 5 | 10 | 5 | 0 | 55 | $90.96 | +1.1% | ▲ $96.33 | +9.0% | HOLD | $116.4B | $4.06 | $6.40 | +40.7% | 2026-11-17 |
| 10 | MRNA | Moderna, Inc. | Biotechnology | AdvancingMomentum Trend | 10 | 0 | 0 | 0 | 5 | 5 | 10 | 5 | 10 | 45 | $143.97 | +472.7% | ▼ $99.24 | -33.3% | WEAK | $57.5B | $-7.98 | $-4.59 | — | 2026-11-05 |
| # | Ticker | Name | Industry | Stage | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | Total | Price | 1yr Chg | 30d Target | 90d Ret | Signal | Mkt Cap | TTM EPS | Fwd EPS | EPS Growth | Next Earnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics, Inc. | Biotechnology | AdvancingMomentum Trend | 10 | 5 | 5 | 0 | 10 | 5 | 10 | 5 | 10 | 60 | $114.96 | +164.2% | ▲ $128.99 | +22.9% | HOLD | $9.5B | $-3.25 | $-4.95 | — | 2026-11-03 |
| 2 | INSM | Insmed Incorporated | Biotechnology | ToppingDistribution Risk | 5 | 5 | 10 | 10 | 5 | 0 | 10 | 5 | 10 | 60 | $129.41 | -10.8% | ▼ $121.90 | +5.5% | WEAK | $28.3B | $-4.12 | $0.80 | — | 2026-10-29 |
| 3 | EDIT | Editas Medicine, Inc. | Biotechnology | ToppingDistribution Risk | 10 | 5 | 5 | 0 | 10 | 0 | 10 | 5 | 10 | 55 | $2.70 | -2.2% | ▲ $3.46 | -38.1% | HOLD | $415M | $-0.66 | $-0.75 | — | 2026-11-09 |
| 4 | TWST | Twist Bioscience Corporation | Biotechnology | AdvancingMomentum Trend | 5 | 5 | 5 | 5 | 10 | 5 | 10 | 5 | 5 | 55 | $127.22 | +393.9% | ▲ $149.90 | +46.4% | HOLD | $8.4B | $-2.23 | $-0.63 | — | 2026-11-16 |
| 5 | DOCS | Doximity, Inc. | Health Information Services | ToppingDistribution Risk | 10 | 5 | 5 | 10 | 0 | 5 | 10 | 5 | 5 | 55 | $25.58 | -63.1% | ▲ $31.53 | -57.1% | HOLD | $4.6B | $0.84 | $1.55 | -51.9% | 2026-11-05 |
| 6 | CRSP | CRISPR Therapeutics AG | Biotechnology | ToppingDistribution Risk | 10 | 5 | 0 | 0 | 5 | 5 | 10 | 5 | 10 | 50 | $51.72 | -5.7% | ▲ $59.29 | -13.3% | HOLD | $5.0B | $-4.71 | $-3.50 | — | 2026-11-09 |
| 7 | BEAM | Beam Therapeutics Inc. | Biotechnology | ToppingDistribution Risk | 10 | 0 | 5 | 0 | 5 | 5 | 10 | 5 | 10 | 50 | $23.99 | +14.9% | ▲ $37.12 | +40.2% | HOLD | $2.5B | $-0.69 | $-4.74 | — | 2026-11-03 |
| 8 | NTLA | Intellia Therapeutics, Inc. | Biotechnology | ToppingDistribution Risk | 10 | 0 | 5 | 0 | 5 | 5 | 10 | 5 | 10 | 50 | $11.74 | -2.7% | ▲ $20.15 | -8.4% | HOLD | $1.6B | $-3.34 | $-2.60 | — | 2026-11-05 |
| 9 | RVMD | Revolution Medicines, Inc. | Biotechnology | AdvancingMomentum Trend | 5 | 5 | 10 | 0 | 10 | 5 | 10 | 5 | 0 | 50 | $203.77 | +403.1% | ▲ $243.97 | +43.6% | HOLD | $43.7B | $-8.86 | $-5.85 | — | 2026-11-04 |
| 10 | IMVT | Immunovant, Inc. | Biotechnology | AdvancingMomentum Trend | 10 | 5 | 0 | 0 | 10 | 5 | 10 | 5 | 0 | 45 | $37.36 | +118.0% | ▲ $44.00 | +33.9% | HOLD | $7.7B | $-2.81 | $-2.75 | — | 2026-11-09 |
| 11 | RXRX | Recursion Pharmaceuticals, Inc. | Biotechnology | DecliningContrarian Setup | 10 | 0 | 0 | 0 | 0 | 0 | 10 | 5 | 10 | 35 | $3.20 | -30.6% | ▲ $3.83 | +5.8% | HOLD | $1.7B | $-1.00 | $-0.89 | — | 2026-11-04 |
| 12 | HIMS | Hims & Hers Health, Inc. | Drug Manufacturers - Specialty & Generic | AdvancingMomentum Trend | 0 | 5 | 0 | 10 | 5 | 0 | 5 | 0 | 0 | 25 | $27.51 | -43.2% | ▲ $32.05 | -28.1% | HOLD | $6.4B | $-0.64 | $0.76 | — | 2026-11-09 |
| # | Ticker | Name | Industry | Stage | C1 | C2 | C3 | C4 | C5 | C6 | C7 | C8 | C9 | Total | Price | 1yr Chg | 30d Target | 90d Ret | Signal | Mkt Cap | TTM EPS | Fwd EPS | EPS Growth | Next Earnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | XLV | State Street Health Care Select Sector SPDR ETF | Pharma | Insufficient Data | 5 | 5 | 5 | 5 | 5 | 10 | 5 | 5 | 0 | 45 | $165.36 | +28.9% | — | — | — | — | — | — | — | — |